Phillip Md Et Al Frost Acquires 200,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average price of $1.74 per share, with a total value of $348,000.00. Following the transaction, the chief executive officer now owns 213,501,448 shares in the company, valued at $371,492,519.52. The trade was a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, February 28th, Phillip Md Et Al Frost acquired 67,434 shares of OPKO Health stock. The shares were purchased at an average price of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.79 on Wednesday. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $2.04. The stock has a market cap of $1.20 billion, a PE ratio of -9.42 and a beta of 1.70. The firm’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.57.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. Analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OPK has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, March 12th. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Wednesday, March 12th.

Institutional Investors Weigh In On OPKO Health

A number of large investors have recently added to or reduced their stakes in OPK. Rubric Capital Management LP grew its stake in OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after acquiring an additional 4,284,336 shares during the last quarter. Millennium Management LLC grew its stake in OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after acquiring an additional 2,112,382 shares during the last quarter. Lazard Asset Management LLC grew its stake in OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after acquiring an additional 1,502,342 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in OPKO Health in the 4th quarter valued at about $2,082,000. Finally, Norges Bank acquired a new stake in OPKO Health in the 4th quarter valued at about $1,657,000. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.